ARS Pharma schedules Type A meeting with FDA for allergy drug; shares rise

ARS Pharmaceuticals

06/10/2023 14:49

** Shares of drug developer ARS Pharmaceuticals  SPRY.O 
rise 1.5% to $4.05
    ** Co says it has scheduled a Type A meeting in October to
discuss contents of letter where FDA declined to approve neffy,
its nasal drug for allergies
    ** Type A meetings are reserved for discussions for stalled
product development program or to address important safety issue
- FDA
    ** Including session moves, shares down 53.2% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))